

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for May 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Orimed Pharma	Flexeril	FLEXERIL	cyclobenzaprine HCl	10mg	tablet	02495422
Sandoz Canada Inc	Sandoz Miglustat	Zavesca	miglustat	100mg	capsule	02456257
Taro Pharmaceuticals Inc.	Taro- Clotrimazole/ Betamethasone Dipropionate	LOTRIDERM CREAM	clotrimazole and betamethasone dipropionate	1% w/w & 0.05% w/w	topical cream - 15g	02496410
Taro Pharmaceuticals Inc.	Taro- Clotrimazole/ Betamethasone Dipropionate	LOTRIDERM CREAM	clotrimazole and betamethasone dipropionate	1% w/w & 0.05% w/w	topical cream - 50g	02496410
Nora Pharma	NRA- Montelukast	Singulair	montelukast sodium	10mg	tablet	02489821

Mylan Pharmaceuticals ULC	Myl- Esomeprazole	Nexium	esomeprazole magnesium trihydrate	20mg	DR tablet	02479419
Mylan Pharmaceuticals ULC	Myl- Esomeprazole	Nexium	esomeprazole magnesium trihydrate	40mg	DR tablet	02479427